Figure 1 | Signal Transduction and Targeted Therapy

Figure 1

From: Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report

Figure 1

Clinical protocol design. Patients with tumors that had a diameter <5 cm or who had ⩽3 lesions provided samples of peripheral blood mononuclear cells from which CART cells were prepared 10–12 days before infusion. Within this time, some patients were given lymphocyte-depleting chemotherapy as described. The infusion was given using a split-dose approach over 4–5 days. Endpoint assays were conducted on study weeks 4–6. CART cells, Chimeric Antigen Receptor-modified T cells; PET-CT, positron emission tomography-computed tomography.

Back to article page